Research and Clinical Trials

Brief Description  
Brivanib is a highly potent oral inhibitor of VEGFR 2 (vascular endothelial growth factor receptor) and FGFR (fibroblast growth factor receptor). Both are proteins that are involved in tumor blood vessels and tumor cell growth. Patients on this study will take brivanib by mouth daily until their disease worsens or unacceptable side effects occur. After agreeing to participate in this study by signing the informed consent, the subject will undergo eligibility testing as follows: Medical histo
Who may be Eligible  
Subjects with persistent or recurrent squamous cell carcinoma, adenosquamous carcinoma, adenocarcinoma, or non-squamous cell carcinoma of the cervix with worsening disease after prior therapy. Subjects must have received at least one but no more than 2 prior chemotherapy regimens for cervical cancer. Previous non-cytotoxic (biologic) treatment for recurrent or persistent disease is not allowed. Subjects must have measurable disease on CT scan or MRI (at least 1 solid lesion at least 1cm or larger). Subjects must have adequate blood counts, kidney and liver function. Subjects may not have a concurrent or previous cancer within the past 5 years. Subjects must have normal thyroid function. Subjects may not have active/known HIV, Hepatitis B or Hepatitis C. Blood pressure must be under good control. Subjects may not be taking therapeutic doses of Coumadin (an oral blood thinner) while on this study.
Gynecological Cancer
IRB Number  
Principal Investigator  
Higgins, Robert

For More Information, Contact  Sarah  , Norek
Phone:  (704) 355-1520  Fax:  (704) 355-9897  
Address:Blumenthal Cancer Center 1025 Morehead Medical Drive Suite 600 Charlotte, NC 28204